Joint Development Agreement with 4basebio PLC for novel CAR T-cell production methods
Leucid Bio: Joint Development Agreement with 4basebio PLC for novel CAR T-cell production methods
4basebio PLC (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines, is pleased to announce a Joint Development Agreement (“JDA”) between its wholly owned subsidiary 4basebio Discovery Limited and Leucid Bio Limited, a biotech company pioneering next-generation Chimeric Antigen Receptor T-Cell (“CAR-T”) Therapies for hard-to-treat cancers.
CAR-T therapy is an ex-vivo cell therapy which involves genetically reprogramming a patient’s T-cells to recognise and destroy cancer cells. While current practice relies on integrating viral vectors to deliver the genetic payloads to generate the CAR T-cells, non-viral based approaches, such as MaxCyte’s electroporation technology, are gaining popularity given their scalability, improved safety profile and flexibility in delivering payloads aimed at creating allogeneic, off-the-shelf CAR T-cells.
